Shining light on reprogramming Tregs for cancer therapy
- PMID: 36931248
- DOI: 10.1016/j.chembiol.2023.02.009
Shining light on reprogramming Tregs for cancer therapy
Abstract
In this issue of Cell Chemical Biology, Bonazzi et al. demonstrate that pharmacologically degrading the transcription factor Helios (IKZF2) results in destabilization of regulatory T cells, which normally restrain anti-tumor immunity. These results highlight how molecular glue degraders can selectively target previously undruggable proteins with potential applications in the clinic.
Copyright © 2023 Elsevier Ltd. All rights reserved.
Comment on
-
Discovery and characterization of a selective IKZF2 glue degrader for cancer immunotherapy.Cell Chem Biol. 2023 Mar 16;30(3):235-247.e12. doi: 10.1016/j.chembiol.2023.02.005. Epub 2023 Mar 1. Cell Chem Biol. 2023. PMID: 36863346
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical